NCT00722761View on ClinicalTrials.gov

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Acne Vulgaris
Interventions
DRUG

drospirenone and ethinyl estradiol

Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks

DRUG

Placebo tablet

Placebo tablet (no active drug) given once daily for 24 weeks

Trial Locations (1)

02114

Clinical Unit for Research Trials in Skin, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00722761 - Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne | Biotech Hunter | Biotech Hunter